Comparative Efficacy and safety of new targeted therapies and immunotherapies for metastatic triple negative breast cancer: a network meta-analysis
| Autor: | John Hang, Leung, Yun-Sheng, Tai, Shyh-Yau, Wang, Ho, Tsung-Chin, Hei-Tung, Yip Fion, Agnes Lf, Chan, Hsu, Yu-Chen |
|---|---|
| Rok vydání: | 2022 |
| Předmět: | |
| Zdroj: | Expert Opinion on Drug Safety. 22:243-252 |
| ISSN: | 1744-764X 1474-0338 |
| DOI: | 10.1080/14740338.2022.2116001 |
| Popis: | Several therapies directed at novel targets and also immunotherapies have recently shown promising results in advanced or metastatic TNBC. We aimed to compare the efficacy and safety of these new regimens for advanced or metastatic TNBC (mTNBC).The PubMed, Embase, and Cochrane Library electronic databases were searched for phase III randomized trials. We conducted a network meta-analysis to compare the efficacy and safety of new targeted and immunotherapy regimens. Trial quality was assessed using the GRADE method. The comparative outcomes were progression-free survival, overall survival, and G3-4 adverse drug events (ADEs).Thirteen phase III randomized controlled trials were identified in the network meta-analysis. Olaparib significantly improved PFS in comparison with the pembrolizumab plus chemotherapy 1, atezolizumab plus nab-paclitaxel and pembrolizumab regimens. Sacituzumab yielded a significant improvement in OS over immunotherapies, veliparib, and chemotherapy alone, but no significantly superiority over pembrolizumab, olaparib, and talazoparib. The risk of ≥grade 3 ADEs associated with olaparib was significantly lower than the risks associated with the other regimens.For mTNBC, sacituzumab had a better effect on overall survival, with comparatively high risk of SAE, whereas olaparib improved progression-free survival with a lower risk of SAE, particularly in those patients with BRCA mutations. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|